Thông tin kê toa tóm tắt
Chỉ định/Công dụng
Atypical depression.
Liều dùng/Hướng dẫn sử dụng
Adult : PO Initial: 15 mg tid, increase to 4 times daily after 2 weeks according to response. Gradually reduce to usual maintenance dose: 15 mg every other day.
Dosage Details
Atypical depression
Adult: Initially, 15 mg tid, increase to 4 times daily after 2 weeks according to response. Gradually reduce to usual maintenance dose: 15 mg every other day.
Special Patient Group
Hospitalised patients: Up to 30 mg tid.
Renal Impairment
Severe: Contraindicated.
Hepatic Impairment
Chống chỉ định
Cerebrovascular disease, phaeochromocytoma, abnormal LFTs or history of hepatic disease. Hepatic and severe renal impairment. Within 10 days of use with general anaesthesia for elective surgery. Concomitant or within 14 days of discontinuing treatment with MAOIs, bupropion, and SSRIs. Concomitant use with dextromethorphan, CNS depressants (e.g. alcohol, pethidine), guanethidine. Tyramine-rich food.
Thận trọng
Patient with major depressive disorder, and other psychiatric disorders, bipolar disorder, risk for hypotension, hypertension, cerebrovascular disease, CV disease, diabetes mellitus, angle-closure glaucoma, hypovolaemia, risk or history of seizure, hyperthyroidism. Elderly. Children, adolescent and young adults. Pregnancy and lactation. Avoid abrupt withdrawal and dose reduction.
Phản ứng phụ
Significant: Suicidality, CNS depression, postural hypotension, shift to hypomania or mania, intracranial bleeding, sensitisation to insulin, pyridoxine deficiency, withdrawal syndrome.
Blood and lymphatic system disorders: Blood dyscrasias.
Cardiac disorders: Arrhythmias.
Eye disorders: Blurred vision, nystagmus, glaucoma.
Gastrointestinal disorders: Nausea, vomiting, dry mouth, constipation.
General disorders and administration site conditions: Weakness, fatigue, oedema, sweating.
Investigations: Elevated serum transaminases, increased weight.
Metabolism and nutrition disorders: Hypermetabolic syndrome, hypo/hypernatraemia, increased appetite.
Musculoskeletal and connective tissue disorders: Twitching, muscle tremor, lupus-like illness.
Nervous system disorders: Dizziness, drowsiness, myoclonic movement, hyperreflexia, headache, paraesthesia, peripheral neuritis, convulsions, palilalia.
Psychiatric disorders: Insomnia, nervousness, euphoria, behavioural changes, jitteriness, confusion, hallucinations.
Renal and urinary disorders: Difficulty in micturition.
Reproductive system and breast disorders: Impotence, delayed ejaculation.
Skin and subcutaneous tissue disorders: Rash, pruritus, purpura.
Potentially Fatal: Hypertensive crises associated with intracranial bleeding. Rarely, progressive necrotising hepatocellular damage, neuroleptic malignant syndrome.
Thông tin tư vấn bệnh nhân
This drug may impair cognitive ability, if affected, do not drive or operate machinery.
Monitor blood pressure, blood glucose, heart rate, renal function and LFT. Monitor for mental status, worsening of depression, suicidality, and unusual changes in behaviour prior to initiation of therapy and every dose titration.
Quá liều
Symptoms: Hypomania, euphoria, coma with hypotension or acute hypertension with or without subarachnoid haemorrhage, extra-pyramidal symptoms; agitation, convulsions, cool and clammy skin, diaphoresis, dizziness, drowsiness, faintness, hallucinations, severe headache, hyperactivity, hyperpyrexia, rapid and irregular pulse, irritability, opisthotonos, precordial pain, respiratory depression and failure, rigidity, trismus. Management: Symptomatic and supportive treatment. Perform gastric lavage with charcoal slurry. Support respiration by airway management, supplemental oxygen and mechanical ventilation if necessary. Consider IV therapy to maintain fluid and electrolyte balance, hypotension, and vascular collapse. May administer phentolamine IV for hypertension; slow IV diazepam inj for CNS stimulation.
Tương tác
May potentiate the effects of antihypertensives (e.g. β-blockers, thiazide diuretics), antimuscarinics, hypoglycaemic agents, anti-Parkinson agents, and local anaesthetics.
Potentially Fatal: Hypertensive crises with other MAOIs, sympathomimetics (e.g. amphetamines, cocaine, dopamine, ephedrine, epinephrine, norepinephrine, methylphenidate) and related compound (e.g. levodopa, methyldopa). Serotonin syndrome with SSRIs, SNRIs, and dextromethorphan. May potentiate the effects of CNS depressants and certain narcotics (e.g. pethidine). Increased hypotensive effect with spinal anaesthesia. Increased blood pressure with bupropion, buspirone, guanethidine. Hypertensive crises and fatal reactions with dibenzazepine derivatives (e.g. TCAs, carbamazepine, perphenazine).
Food Interaction
Hypertensive crises with high concentration of tyramine, dopamine, phenylalanine, tyrosine, caffeine and chocolate. Behavioural and neurologic symptoms with high concentration of tryptophan. May potentiate the effects of alcohol.
Tác dụng
Description: Phenelzine inhibits both type A and type B monoamine oxidase (MAO), an enzyme responsible for the breakdown of biogenic amines. The exact mechanism of action has not been fully understood, but it is though that the increase in endogenous concentration of amine neurotransmitters (e.g. norepinephrine, dopamine and serotonin) within the CNS causes its antidepressant effect.
Onset: ≥4 weeks.
Absorption: Readily absorbed from the gastrointestinal tract. Time to peak plasma concentration: 43 minutes.
Metabolism: Extensively metabolised primarily via oxidation by MAO and via acetylation into N2-acetylphenelzine (minor pathway).
Excretion: Mainly via urine (73%, as phenylacetic acid and parahydroxyphenylacetic acid metabolites). Elimination half-life: 11.6 hours.
Đặc tính

Click on icon to see table/diagram/image
Bảo quản
Store between 2-8°C. Do not freeze.
Phân loại MIMS
Phân loại ATC
N06AF03 - phenelzine ; Belongs to the class of non-selective monoamine oxidase inhibitors. Used in the management of depression.
Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Phenelzine từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2020 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in